Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 12/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 7/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382023 | 1.00 | PNMT (1.00) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL27698594 | 0.98 | PNMT (0.97) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL29651180 | 0.98 | PNMT (0.97) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL325622 | 0.98 | PNMT (0.97) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL1269277 | 0.93 | PNMT (0.87) | PNMTADRA2AADRA2BADRA2C | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL5485986 | 0.92 | PNMT (0.85) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL10004303 | 0.92 | PNMT (0.84) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL1074232 | 0.90 | PNMT (0.82) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL717840 | 0.89 | PNMT (0.81) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL1947220 | 0.88 | PNMT (0.78) | PNMTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 558 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118619800-A | Amino dithioformate compound and preparation method thereof | 抚州三和医药化工有限公司 | 2024-09-10 | — | — | CN | claimed |
| CN-111621805-B | Method for preparing 3, 4-dihydroisoquinoline by electrocatalytic selective dehydrogenation | 天津大学 | 2022-02-18 | — | — | CN | claimed |
| CN-111621805-A | Method for preparing 3, 4-dihydroisoquinoline by electrocatalytic selective dehydrogenation | 天津大学 | 2020-09-04 | — | — | CN | claimed |
| CN-107827817-B | Method for synthesizing formamide derivative through molybdenum catalytic formylation reaction | 湘潭大学 | 2020-03-13 | — | — | CN | claimed |
| CN-107827816-B | Method for synthesizing formamide derivative through graphene oxide catalytic formylation reaction | 湘潭大学 | 2020-01-10 | — | — | CN | claimed |
| CN-107892670-B | Method for synthesizing formamide derivative through cobalt-catalyzed formylation reaction | 湘潭大学 | 2019-12-13 | — | — | CN | claimed |
| CN-107089980-B | A kind of chirality benzo [a] quinolizine -2- ketone compounds and its asymmetry catalysis synthetic method | 合肥工业大学 | 2019-08-30 | — | — | CN | claimed |
| CN-107089980-A | A kind of ketone compounds of chiral benzo [a] quinolizine 2 and its asymmetry catalysis synthetic method | 合肥工业大学 | 2017-08-25 | — | — | CN | claimed |
| EP-1227803-B1 | COMPOUNDS FOR INHIBITING IAPP-ASSOCIATED AMYLOID DEPOSITS | BELLUS HEALTH INTERNATIONAL LTD (CH) | 2010-05-05 | — | — | EP | claimed |
| US-6562836-B1 | Islet amyloid polypeptide (IAPP) is known to be capable of forming fibrils which are deposited in the pancreas of patients wtih type II diabetes | QUEEN'S UNIVERSITY OF KINGSTON (CA) | 2003-05-13 | — | — | US | claimed |
| US-12617785-B2 | Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss | THE ROCKEFELLER UNIVERSITY (US) | 2026-05-05 | — | — | US | disclosed |
| US-12612413-B2 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2026-04-28 | — | — | US | disclosed |
| EP-4720038-A1 | (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES | Neophore Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | Lee Moffitt Cancer Center and Research Institute, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4642767-A1 | PYRIMIDINE CARBOXAMIDE COMPOUNDS | Acrivon Therapeutics, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| WO-1996035713-A1 | DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE | PFIZER, INC. (US) | 1996-11-14 | — | — | WO | disclosed |
| EP-0738150-A1 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-10-23 | — | — | EP | disclosed |
| WO-1996024588-A1 | BICYCLIC ISOTHIOUREA DERIVATIVES USEFUL IN THERAPY | ASTRA AKTIEBOLAG (SE) | 1996-08-15 | — | — | WO | disclosed |
| EP-0709370-A1 | Bicyclic compounds useful as platelet aggregation inhibitors | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995018619-A1 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612413-B2 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | CASP6, CASP3, BAX | PNMT 4713/4885ADRA2A 2427/4885ADRA2B 2093/4885 |
| US-12617785-B2 | Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss | YAP1, LATS2, LATS1 | PNMT 3487/4885ADRA2A 4132/4885ADRA2B 3575/4885 |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | CRBN, CD4, ICOS | PNMT 2734/4885ADRA2A 1489/4885ADRA2B 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.